Sirion - Ophthalmology Innovation Summit

More documents

Recommendations

Info

<strong>Sirion</strong>: An Emerging Leader in Ophthalmic Pharmaceuticals • Founded in November 2005 by former senior executives of ophthalmic companies • Two approved products and three pipeline products for front of the eye indications • Leading dry AMD research program for geographic atrophy • In-house discovery and development capabilities, with background as a CRO 1
<strong>Sirion</strong> Product Pipeline DurezolTM (difluprednate ophthalmic emulsion) Durezol 0.05% Ganciclovir Ophthalmic Gel 0.15% Zirgan Ocular Surgery Herpetic Keratitis Approved Approved Cyclosporine Ophthalmic Zyclorin Solution 0.1% Dry Eye Phase III Fenretinide Fenretinide Dry AMD Phase II ST-802 ST-802 Glaucoma Phase I/II Norketotifen Allergy Preclinical SIR-1046 SIR-1046 Dry AMD Preclinical SIR-1076 Dry AMD Preclinical 2
Page 4 and 5: Durezol Overview •Product attribu
Page 6 and 7: Zirgan Overview •Product attribut
Page 8 and 9: Fenretinide Overview •Target dise
Page 10 and 11: Preliminary Findings Based on inter
Page 12 and 13: Other Pipeline Products •IND Stag

Sirion - Ophthalmology Innovation Summit

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?